Enterprise Value
417.7M
Cash
760.6M
Avg Qtr Burn
-10.97M
Short % of Float
12.04%
Insider Ownership
28.09%
Institutional Own.
43.65%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bebtelovimab (LY-CoV1404) Details COVID-19 | Approved Update | |
Bamlanivimab (LY-CoV555) Details COVID-19 | Approved Quarterly sales |